{
    "id": 3192,
    "name": "neurilemmoma",
    "source": "DOID",
    "definition": null,
    "currentPreferredTerm": null,
    "lastUpdateDateFromDO": "03/24/2020",
    "altIds": [
        
    ],
    "termId": "DOID:3192",
    "evidence": [
        {
            "id": 2237,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Nexavar (sorafenib) inhibited PDGFRB, ERK1/2, and AKT activity and blocked cell proliferation in cultured human primary schwannomas deficient in NF2 (PMID: 18593924).",
            "molecularProfile": {
                "id": 6530,
                "profileName": "NF2 loss"
            },
            "therapy": {
                "id": 920,
                "therapyName": "Sorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 3192,
                "name": "neurilemmoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2821,
                    "pubMedId": 18593924,
                    "title": "Dissecting and targeting the growth factor-dependent and growth factor-independent extracellular signal-regulated kinase pathway in human schwannoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/18593924"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2240,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AR-42 reduced activation of AKT and inhibited growth NF2-deficient primary human schwannoma cells and schwannoma cell lines in culture, and induced apoptosis and inhibited tumor growth in cell line xenograft models of NF2-deficient malignant schwannoma (PMID: 21778190).",
            "molecularProfile": {
                "id": 6530,
                "profileName": "NF2 loss"
            },
            "therapy": {
                "id": 987,
                "therapyName": "AR-42",
                "synonyms": null
            },
            "indication": {
                "id": 3192,
                "name": "neurilemmoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2816,
                    "pubMedId": 21778190,
                    "title": "AR42, a novel histone deacetylase inhibitor, as a potential therapy for vestibular schwannomas and meningiomas.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21778190"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2248,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Gleevec (imatinib mesylate) inhibited growth and viability of human schwannoma cell lines deficient in NF2 (PMID: 19509233).",
            "molecularProfile": {
                "id": 6530,
                "profileName": "NF2 loss"
            },
            "therapy": {
                "id": 770,
                "therapyName": "Imatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3192,
                "name": "neurilemmoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2831,
                    "pubMedId": 19509233,
                    "title": "Human schwannomas express activated platelet-derived growth factor receptors and c-kit and are growth inhibited by Gleevec (Imatinib Mesylate).",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19509233"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11321,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, human schwann cells expressing SH3PXD2A-HTRA1 demonstrated cell growth inhibition and abrogated expression of phosphorylated Mapk and Erk in culture when treated with Mekinist (trametinib) (PMID: 27723760).",
            "molecularProfile": {
                "id": 27958,
                "profileName": "SH3PXD2A - HTRA1"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 3192,
                "name": "neurilemmoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9239,
                    "pubMedId": 27723760,
                    "title": "The genomic landscape of schwannoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27723760"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11322,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, human schwann cells harboring a NF2 mutation and expressing SH3PXD2A-HTRA1 demonstrated cell growth inhibition and abrogated expression of phosphorylated Mapk and Erk in culture when treated with Mekinist (trametinib) (PMID: 27723760).",
            "molecularProfile": {
                "id": 27959,
                "profileName": "SH3PXD2A - HTRA1 NF2 mut"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 3192,
                "name": "neurilemmoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9239,
                    "pubMedId": 27723760,
                    "title": "The genomic landscape of schwannoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27723760"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "clinicalTrials": [
        {
            "nctId": "NCT03095248",
            "title": "Trial of Selumetinib in Patients With Neurofibromatosis Type II Related Tumors",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 913,
                    "therapyName": "Selumetinib",
                    "synonyms": null
                }
            ]
        }
    ]
}